Iovance Biotherapeutics, Inc. (IOVA) financial statements (2021 and earlier)

Company profile

Business Address 999 SKYWAY ROAD
SAN CARLOS, CA 94070
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:63530738614516710445
Cash and cash equivalents6714821451071445
Short-term investments562293  6070 
Other undisclosed cash, cash equivalents, and short-term investments6 304 020 
Other undisclosed current assets19894300
Total current assets:63631647514917010445
Noncurrent Assets
Operating lease, right-of-use asset5511
Property, plant and equipment59932222
Other noncurrent assets13334   
Other undisclosed noncurrent assets65     
Total noncurrent assets:1322856222
TOTAL ASSETS:76834548115517210647
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities49321410522
Accounts payable141631111
Accrued liabilities3516129410
Debt 7     
Due to related parties     00
Other undisclosed current liabilities6      
Total current liabilities:55391410522
Noncurrent Liabilities
Long-term debt and lease obligation454     
Operating lease, liability454
Liabilities, other than long-term debt1220    
Deferred rent credit  0
Other liabilities122     
Total noncurrent liabilities:5770    
Total liabilities:112461510522
Stockholders' equity
Stockholders' equity attributable to parent, including:65629946614516710445
Preferred stock      0
Common stock0000000
Additional paid in capital1,487869839395324208121
Accumulated other comprehensive income (loss)00(0) 00 
Accumulated deficit(830)(571)(373)(249)(157)(104)(77)
Other undisclosed stockholders' equity attributable to parent0000000
Total stockholders' equity:65629946614516710445
TOTAL LIABILITIES AND EQUITY:76834548115517210647

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:     (4) 
Operating expenses(262)(207)(128)(93)(54)(28)(12)
Other undisclosed operating income     4 
Operating loss:(262)(207)(128)(93)(54)(28)(12)
Nonoperating income2951100
Investment income, nonoperating29511  
Other nonoperating income     00
Interest and debt expense      0
Loss before gain (loss) on sale of properties:(260)(198)(124)(92)(53)(28)(12)
Other undisclosed net loss      (0)
Net loss attributable to parent:(260)(198)(124)(92)(53)(28)(12)
Preferred stock dividends and other adjustments    (49)  
Net loss available to common stockholders, diluted:(260)(198)(124)(92)(102)(28)(12)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(260)(198)(124)(92)(53)(28)(12)
Comprehensive loss:(260)(198)(124)(92)(53)(28)(12)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0(0)(0)(0)0 
Comprehensive loss, net of tax, attributable to parent:(260)(197)(124)(92)(53)(28)(12)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: